-
Marimastat was a
proposed antineoplastic drug
developed by
British Biotech. It
acted as a broad-spectrum
matrix metalloproteinase inhibitor. Marimastat...
- $2.5 billion,
largely on the
basis of its two main
development drugs:
marimastat (a
novel matrix metalloprotease inhibitor for
cancer treatment) and lexipafant...
-
suspected to be
involved in (see above). However, most of these, such as
marimastat (BB-2516), a broad-spectrum MMP inhibitor, and
cipemastat (Ro 32-3555)...
-
called "hydroxamate-based MMP inhibitors“. An
example can be seen in
Marimastat, a
first generation inhibitor,
which has a
similar backbone and sidechain...
-
generally safe with
minimal adverse side effects. Additionally,
trials with
marimastat did show a
slight increase in
survival of
patients with
gastric or pancreatic...
-
administered orally (as
opposed to the
newer and
chemically similar MMPI
marimastat), and
injection into the
peritoneum caused peritonitis. It is well-known...
- as
anticancer drugs.
Examples include:
Batimastat Cipemastat Ilomastat Marimastat Prinomastat Tanomastat Metalloproteinase inhibitors are
found in numerous...
-
lymphoma –
mammary –
mammogram –
mammography –
Mammotome –
mantle field –
marimastat – mast cell –
mastectomy –
mastocytoma –
matrix metalloproteinase – MDL...
- with
these compounds have to date
produced equivocal results.
Batimastat Marimastat Coussens, L. M. (2002). "Matrix
Metalloproteinase Inhibitors and Cancer--Trials...
- inhibitors, DPP-4 inhibitors, and
exogenous MMP
inhibitors like
batimastat and
marimastat.
Various enkephalinase inhibitors, such as ketalorphan, spinorphin, and...
